{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"181.783","value":"254.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"}],"units":"Participants"}],"title":"Cycle 1 Day 1 (2h Postdose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.078","value":"22.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (Predose)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"138.310","value":"198.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"title":"Cycle 2 Day 1 (2h Postdose)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib 160 mg twice a day orally with or without food; Obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2 to 6; and then every 8 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; each cycle is 28 days","id":"OG000","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetics (PK) Analysis Set included all zanubrutinib-treated participants who had at least one post-baseline PK concentration measurement.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1: Predose (within 30 minutes before zanubrutinib dosing) and 2 hours (± 30 minutes) post-dose.","title":"Zanubrutinib Plasma Concentrations","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/ml)"}